Chapin Davis Inc. Buys 6,094 Shares of Axon Enterprise, Inc $AXON

Key Points

• Chapin Davis Inc. increased its stake in Axon Enterprise, Inc by 989.3%, now holding 6,710 shares valued at $5.56 million, making it the 15th largest position in their portfolio.
• Axon Enterprise reported $2.12 earnings per share for the last quarter, surpassing analyst estimates of $1.54, with a year-over-year revenue increase of 32.6%.
• The company's stock has a market cap of $60.80 billion and is currently rated as a "Moderate Buy" by analysts, with a consensus target price of $837.69.

Chapin Davis Inc. increased its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 989.3% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,710 shares of the biotechnology company's stock after purchasing an additional 6,094 shares during the quarter. Axon Enterprise accounts for approximately 1.5% of Chapin Davis Inc.'s portfolio, making the stock its 15th biggest position. Chapin Davis Inc.'s holdings in Axon Enterprise were worth $5,555,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of AXON. LaSalle St. Investment Advisors LLC boosted its stake in Axon Enterprise by 2.1% in the first quarter. LaSalle St. Investment Advisors LLC now owns 777 shares of the biotechnology company's stock valued at $408,000 after acquiring an additional 16 shares in the last quarter. Smartleaf Asset Management LLC raised its stake in shares of Axon Enterprise by 5.0% during the first quarter. Smartleaf Asset Management LLC now owns 379 shares of the biotechnology company's stock worth $203,000 after purchasing an additional 18 shares during the last quarter. Pinion Investment Advisors LLC raised its stake in shares of Axon Enterprise by 3.0% during the first quarter. Pinion Investment Advisors LLC now owns 649 shares of the biotechnology company's stock worth $341,000 after purchasing an additional 19 shares during the last quarter. Kentucky Retirement Systems grew its holdings in Axon Enterprise by 0.4% during the first quarter. Kentucky Retirement Systems now owns 4,953 shares of the biotechnology company's stock worth $2,605,000 after acquiring an additional 19 shares during the period. Finally, WCM Investment Management LLC grew its holdings in Axon Enterprise by 0.8% during the first quarter. WCM Investment Management LLC now owns 2,441 shares of the biotechnology company's stock worth $1,306,000 after acquiring an additional 19 shares during the period. 79.08% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Axon Enterprise

In other news, CEO Patrick W. Smith sold 10,000 shares of Axon Enterprise stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $831.29, for a total value of $8,312,900.00. Following the completion of the transaction, the chief executive officer directly owned 3,053,982 shares of the company's stock, valued at approximately $2,538,744,696.78. This trade represents a 0.33% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, President Joshua Isner sold 15,919 shares of Axon Enterprise stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $746.26, for a total value of $11,879,712.94. Following the transaction, the president owned 238,379 shares of the company's stock, valued at $177,892,712.54. This trade represents a 6.26% decrease in their position. The disclosure for this sale can be found here. Insiders sold 44,932 shares of company stock worth $34,408,816 over the last 90 days. Company insiders own 5.70% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on AXON shares. Raymond James Financial reiterated an "outperform" rating and set a $855.00 target price (up from $645.00) on shares of Axon Enterprise in a research report on Tuesday, August 5th. JPMorgan Chase & Co. raised their price objective on Axon Enterprise from $730.00 to $850.00 and gave the company an "overweight" rating in a research note on Thursday, July 17th. Wolfe Research started coverage on Axon Enterprise in a research note on Monday, July 7th. They set an "outperform" rating for the company. Needham & Company LLC set a $870.00 target price on Axon Enterprise and gave the stock a "buy" rating in a research report on Tuesday, August 5th. Finally, UBS Group reissued a "neutral" rating and issued a $840.00 price target (up previously from $820.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Thirteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $837.69.

Axon Enterprise Price Performance

NASDAQ AXON traded up $1.39 during trading hours on Monday, reaching $775.92. 406,873 shares of the company's stock were exchanged, compared to its average volume of 491,303. The stock has a market cap of $60.91 billion, a PE ratio of 191.59, a price-to-earnings-growth ratio of 28.43 and a beta of 1.40. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63. The firm has a fifty day moving average of $760.48 and a 200-day moving average of $698.43. Axon Enterprise, Inc has a one year low of $388.36 and a one year high of $885.91.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 EPS for the quarter, topping the consensus estimate of $1.54 by $0.58. The business had revenue of $668.54 million for the quarter, compared to the consensus estimate of $641.77 million. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The firm's revenue was up 32.6% compared to the same quarter last year. During the same quarter last year, the business posted $1.20 EPS. Axon Enterprise has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.